These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20533068)

  • 1. Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study.
    Takakuwa M; Iwamoto J; Konishi M; Zhou Q; Itabashi K
    J Bone Miner Metab; 2011 Jan; 29(1):88-95. PubMed ID: 20533068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
    Takakuwa M; Iwamoto J; Itabashi K
    Clin Drug Investig; 2012 Feb; 32(2):121-9. PubMed ID: 22185631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of risedronate in Japanese male patients with primary osteoporosis.
    Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    Intern Med; 2008; 47(8):717-23. PubMed ID: 18421187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
    Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    J Bone Miner Metab; 2009; 27(2):168-74. PubMed ID: 19183836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year experience with risedronate therapy for patients with increased fracture risk: a practice-based observational study.
    Takakuwa M; Iwamoto J
    Biol Pharm Bull; 2015; 38(1):88-95. PubMed ID: 25744463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effect of 4 months of risedronate therapy on femoral strength using femoral strength analysis tools.
    Takakuwa M; Otsuka K; Konishi M; Itabashi K
    J Int Med Res; 2009; 37(6):1972-81. PubMed ID: 20146897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
    Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
    Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
    Ringe JD; Farahmand P; Faber H; Dorst A
    Rheumatol Int; 2009 Jan; 29(3):311-5. PubMed ID: 18762944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
    Ringe JD; Faber H; Farahmand P; Dorst A
    Rheumatol Int; 2006 Mar; 26(5):427-31. PubMed ID: 16001181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
    Siris ES; Simon JA; Barton IP; McClung MR; Grauer A
    Osteoporos Int; 2008 May; 19(5):681-6. PubMed ID: 17968610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB; Geusens P; Barton IP; Felsenberg D
    J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of stopping risedronate after long-term treatment on bone turnover.
    Eastell R; Hannon RA; Wenderoth D; Rodriguez-Moreno J; Sawicki A
    J Clin Endocrinol Metab; 2011 Nov; 96(11):3367-73. PubMed ID: 21865359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
    Sebba AI; Bonnick SL; Kagan R; Thompson DE; Skalky CS; Chen E; de Papp AE;
    Curr Med Res Opin; 2004 Dec; 20(12):2031-41. PubMed ID: 15706659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
    Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture risk remains reduced one year after discontinuation of risedronate.
    Watts NB; Chines A; Olszynski WP; McKeever CD; McClung MR; Zhou X; Grauer A
    Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
    Dundar U; Kavuncu V; Ciftci IH; Evcik D; Solak O; Cakir T
    J Bone Miner Metab; 2009; 27(4):464-70. PubMed ID: 19301089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
    Majima T; Komatsu Y; Doi K; Takagi C; Shigemoto M; Fukao A; Morimoto T; Corners J; Nakao K
    J Bone Miner Metab; 2006; 24(2):105-13. PubMed ID: 16502116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.